In accordance with the Medication Access and Training Expansion (MATE) Act, beginning June 7, 2023, all providers who are registered with the DEA are required to complete 8 hours of training on the treatment and management of patients with opioid and other substance use disorders. This bundle fully satisfies this one-time requirement. | $210 Participants can earn 8.50 CE/CME hours, including 8 pharmacology hours. 8.50 CE/CME category 1 credits; 8 are pharmacology | $210

This fun and enlightening presentation for primary care providers will evaluate safe and effective prescribing by considering more than just medication costs. Cost-effective prescribing also means avoiding drug-drug and drug-disease interactions so that patients get the most out of the medications they take. | 1.5 CE/CME category 1 credits (1.50 Pharmacology) | $40

This dynamic bundle focuses on equipping acute care APPs with the skills and confidence to effectively manage acute patient care. Through case studies, simulations, and guided discussions, participants will learn to quickly recognize early signs of patient deterioration, initiate appropriate interventions, and collaborate with interdisciplinary teams under high-pressure conditions. The sessions cover rapid assessment techniques, communication strategies during emergencies, and documentation best practices to ensure continuity of care. The advanced care provider will leave with enhanced critical thinking abilities and practical tools to improve patient outcomes in acute care situations. This bundle has 8 packed sessions that is a must for any acute care provider. | $160 Participants can earn 7.50 CE/CME hours, including 5 pharmacology hours. 7.50 CE/CME category 1 credits; 5 are pharmacology | $160

This session discusses the diagnosis and treatment of hypogonadism and testosterone replacement. What we can and cannot give and what the latest data tells us. | 1.0 CE/CME category 1 credits (1.00 Pharmacology) | $30

An update on the current landscape of Alzheimer's diagnosis and treatment, characterized by rapid advances in biomarker-driven diagnosis, the emergence of anti-amyloid and anti-tau therapies, and ongoing challenges in translating clinical trial results into real-world practice, including an update on the integration of novel imaging and plasma biomarkers, and the evolving therapeutic pipeline with monoclonal antibodies and other disease-modifying strategies. | 1.0 CE/CME category 1 credits (1.0 Pharmacology) | $30

Selecting, interpreting, and managing hematologic laboratory tests are essential to quality care and often is a complex and challenging process. Interpreting labs is much more complicated than determining if results are normal or anormal. Understanding the normal physiology of blood cell production and the pathophysiology of conditions that can cause abnormalities is important to diagnosing, managing and often preventing pathological hematologic conditions, such as anemia and polycythemia. This presentation will help learners manage these conditions using a systematic approach to selection and interpretation of labs and evidenced based management using case studies for context. | 1.0 CE/CME category 1 credits (0.00 Pharmacology) | $27.50

70% of US adults have obesity or pre-obesity and only 2% are offered pharmacology treatment as part of the evidenced based treatment. It is important for clinicians to know the full evidenced-based management of the disease of obesity. During this presentation the participant will review FDA approved medications and discuss off label options to assist with treatment. | 1.0 CE/CME category 1 credits (1.0 Pharmacology) | $35

Understand the rationale, selection and mechanism of action of antiseizure medication, past and present. | 1.5 CE/CME category 1 credits (1.50 Pharmacology) | $40

Get up to speed on the latest guidelines for preparticipation physicals in youth athletes. This session covers updated screening recommendations, common clearance dilemmas, and practical tips to streamline sports physicals in busy APP practices. | 1.0 CE/CME category 1 credits (0 Pharmacology) | $27.5

This session offers advanced practice providers an up-to-date overview of emerging developments in breast cancer diagnosis and treatment. Participants will review updates in staging, biomarker profiling, and the expanding role of precision medicine. On the treatment side, the session covers new systemic therapies, evolving indications for targeted agents such as CDK4/6 inhibitors, PARP inhibitors, and antibody-drug conjugates, as well as updates in endocrine therapy and immunotherapy. Changes in surgical and radiation approaches—particularly de-escalation strategies aimed at maintaining outcomes while reducing morbidity—will also be discussed. Practical guidance is provided to help APPs integrate these updates into clinical practice, enhance multidisciplinary coordination, and optimize patient education and survivorship care. By the end of the session, APPs will be better equipped to deliver evidence-based, patient-centered care in the rapidly evolving landscape of breast cancer management. | 1.0 CE/CME category 1 credits (0.75 Pharmacology) | $30.00